Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis

Clin Gastroenterol Hepatol. 2017 Oct;15(10):1521-1530.e8. doi: 10.1016/j.cgh.2017.04.039. Epub 2017 May 4.

Abstract

Background & aims: Statins have been variably shown to decrease risk and complications of chronic liver diseases (CLDs). We performed a systematic review and meta-analysis to evaluate the association between statins and risk of cirrhosis and related complications in patients with CLDs.

Methods: Through a systematic literature search up to March 2017, we identified 13 studies (3 randomized trials, 10 cohort studies) in adults with CLDs, reporting the association between statin use and risk of development of cirrhosis, decompensated cirrhosis, improvements in portal hypertension, or mortality. Pooled relative risk (RR) estimates with 95% confidence interval (CIs) were calculated using random effects model. Grading of Recommendations Assessment, Development and Evaluation criteria were used to assess quality of evidence.

Results: Among 121,058 patients with CLDs (84.5% with hepatitis C), 46% were exposed to statins. In patients with cirrhosis, statin use was associated with 46% lower risk of hepatic decompensation (4 studies; RR, 0.54; 95% CI, 0.46-0.62; I2 = 0%; moderate-quality evidence), and 46% lower mortality (5 studies; RR, 0.54; 95% CI, 0.47-0.61; I2 = 10%; moderate-quality evidence). In patients with CLD without cirrhosis, statin use was associated with a nonsignificant (58% lower) risk of development of cirrhosis or fibrosis progression (5 studies; RR, 0.42; 95% CI, 0.16-1.11; I2 = 99%; very-low-quality evidence). In 3 randomized controlled trials, statin use was associated with 27% lower risk of variceal bleeding or progression of portal hypertension (hazard ratio, 0.73; 95% CI, 0.59-0.91; I2 = 0%; moderate-quality evidence).

Conclusions: Based on a systematic review and meta-analysis, statin use is probably associated with lower risk of hepatic decompensation and mortality, and might reduce portal hypertension, in patients with CLDs. Prospective observational studies and randomized controlled trials are needed to confirm this observation.

Keywords: Cholesterol-lowering Drug; Cirrhosis; Liver Fibrosis; Meta-analysis; RCT.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Alcoholism / complications*
  • Fibrosis / epidemiology*
  • Fibrosis / mortality
  • Fibrosis / prevention & control*
  • Hepatitis B, Chronic / complications*
  • Hepatitis C, Chronic / complications*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Liver Failure / epidemiology
  • Liver Failure / mortality
  • Liver Failure / prevention & control
  • Risk Assessment
  • Survival Analysis

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors